share_log

Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate

Benzinga ·  May 2 16:07

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 17.65 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $1.130 million which missed the analyst consensus estimate of $1.401 million by 19.33 percent. This is a 4.61K percent increase over sales of $24.000 thousand the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment